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Introduction 
Rheumatic heart disease is still the most 
frequent etiology of double valve lesions in 
developing countries, and double valve surgery 
accounted for 10.9% of valve surgeries [1]. In 
double valve surgery, myocardial protection has 
crucial importance to improve the outcomes in 
those patients [2]. 
The ideal cardioplegic solution should provide 
excellent myocardial protection, cause minimal 
systemic electrolyte imbalance, and be effective 
for prolonged periods to minimize repeated 
administration [3]. The cardioplegic solutions 
could have intracellular or extracellular 
formulations [4]. Extracellular cardioplegia, such 
as blood cardioplegia, requires frequent infusion 
every 20 minutes to achieve proper myocardial 
protection [5]. Recently, Custodiol® has been used 
as a multi-organ preservation solution. It increases 
perfusion to donors' kidneys, liver and pancreas; 
additionally, it can be used as a cardioplegic 
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Abstract 
Background: Several cardioplegic solutions are available for myocardial 
preservation. The superiority of intracellular over extracellular cardioplegia is still 
debated. Our study aimed to compare the results of Custodiol® and blood 
Cardioplegia for myocardial protection in double valve replacement surgery.
Methods: This is a prospective study that included 301 patients. We grouped the 
patient into; Group A (n= 135) had Custodiol® cardioplegia, and Group B (n= 166) 
had cold blood cardioplegia. We included patients who had double valve surgery and 
excluded redo, emergency procedures, and patients who had concomitant coronary 
artery bypass grafting.  
Results: Patients in Group A were significantly younger (43 ±9 vs. 47 ±10, P<0.001). 
There were 72 females (53.3%) in Group A and 71 (43.4%) in Group B (P= 0.09). The 
total bypass time was higher in group B (217± 40 vs. 179± 35 min, P< 0.001). The 
cross-clamp time was comparable between groups (90± 31 vs. 85± 29 min, P= 0.15). 
The duration of mechanical ventilation (7 ± 1 vs. 12 ± 2 h, P< 0.001), ICU stay (3± 0.7 
vs. 4± 0.9, P< 0.001) and hospital stay (8± 1 vs. 13± 3, P< 0.001) were shorter in Group 
A. Postoperative wound seroma (5 (26.6%) vs. 60 (36.1%), P< 0.001) and mortality 
(2 (1.5%) vs. 11 (6.6%), p= 0.042) were lower in Group A. 
Conclusion: Custodiol cardioplegia could be safe during double valve surgery. A 










solution during cardiac surgery [6]. The single-
dose Custodiol® prevents long-term ischemia and 
provides good solid-organ preservation [7]. 
The superiority of Custodial over cold blood 
cardioplegia is still the subject of several ongoing 
research. The aim of this study was to compare the 
results of Custodiol® and cold blood cardioplegia 
for myocardial protection in double valve surgery. 
Patients and methods: 
Design and patients: 
We conducted a prospective study on 301 
patients who underwent double valve surgery. We 
classified the patients into two groups according 
to the cardioplegic solution used. Group A 
included 135 patients who received Custodiol®, 
and Group B included 166 patients who received 
cold blood cardioplegia.  Cardioplegia was 
selected based on surgeons' preferences and 
patients' ages. We included those who had double 
valve surgery with an ejection fraction of more 
than 50%. Patients who had re-operative surgery, 
emergency operation, and those who had 
concomitant coronary artery bypass grafting were 
excluded. 
Technique 
In Group A, a single dose of HTK solutions at 
4°C (20-25ml/kg) was given over 5–8 min, and the 
systemic temperature was lowered to 30°. We 
infused the cardioplegia in antegrade fashion with 
an initial perfusion pressure of 80–100 mmHg. 
After cardiac arrest, the perfusion pressure was 
maintained at 40–60 mmHg. 
In Group B, we infused cold blood cardioplegia 
through aortic root. The systemic temperature 
was reduced to 28-30 °C, and the hematocrit was 
kept between 21-25%.  Blood cardioplegia was 
mixed at 1:4 (Blood- cardioplegic solution) and 
repeated every 20 minutes. The infusion rate was 
150-180 ml/min for an initial dose of 1 liter and 
subsequent doses of 500 ml each until the 
mechanical mitral valve and aortic valve were 
replaced.  
Endpoints 
The study outcomes were postoperative 
ventilation, ICU, and hospital stay time. 
Echocardiographic follow-up was performed 
within three and six months postoperatively. 
Ethical considerations 
An approval from the Research Ethics 
Committee in the Benha Faculty of Medicine was 
obtained. Informed written consent was obtained 
from all participants before enrollment. 
Statistical analysis 
The collected data were summarized in terms 
of mean ± standard deviation (SD) for quantitative 
data and frequency and percentage for qualitative 
data. Comparisons between proportions were 
carried out using the Chi-square test (χ2) or Fisher 
exact test. Student t-test was used for comparing 
two means. The statistical analysis was conducted 
using the SPSS v21 (IBM Corp- Armonk- NY- USA).
Table 1: Preoperative and operative data. Data were presented as mean and SD or numbers and percentages 
Group A (n= 135) Group B (n= 166) P-value 
Age (years) 43 ±9 47 ±10 <0.001 















Mitral stenosis 135 (100%) 155 (93.4%) 0.001 
Mitral regurgitation 135 (100%) 166 (100%) 
Aortic stenosis 54 (40%) 94 (56.6%) 0.004 
Aortic regurgitation 135 (100%) 166 (100%) 
Cardiopulmonary bypass time (min) 179± 35 217± 40 <0.001 
Cross-clamp time (min) 85± 29 90± 31 0.15 





Table 2: Post-bypass and postoperative data. Data were presented as mean and SD or numbers and percentages 
Group A (n= 135) Group B (n= 166) P-value 
Post bypass Atrial fibrillation 90 (66.6%) 94 (56.7%) 0.003 
Post bypass ventricular tachycardia 22 (16.3%) 55 (33.3%) 0.001 
Post bypass DC shock  112 (83%) 166 (100%) <0.001 














Mechanical ventilation (h) 7 ± 1 12 ± 2 <0.001 
Intensive care stay (days) 3 ± 0.7 4 ± 0.09 <0.001 
Hospital stay (days) 8 ± 1 13 ± 3 <0.001 
Postoperative atrial fibrillation 36 (26.6%) 17 (10.2%) <0.001 
Wound seroma 5 (3.7%) 60 (36.1%) <0.001 
Operative mortality 2 (1.5%) 11 (6.6%) 0.042 
A P-value of less than 0.05 was considered 
statistically significant 
Results: 
Preoperative and operative data: 
Patients in Group A were significantly younger. 
There were 72 females (53.3%) in Group A and 71 
(43.4%) in Group B (P= 0.09). Mitral and aortic 
regurgitation were the dominant lesions in both 
groups, while mitral stenosis was more in Group A 
and aortic stenosis was more in Group B. The total 
bypass time was higher in group B (217± 40 vs. 
179± 35 min, P< 0.001). The cross-clamp time was 
longer in Group B but did not reach a significant 
level (90± 31 vs. 85± 29 min, P= 0.15). (Table 1)  
Postoperative outcomes 
Post-bypass ventricular tachycardia and atrial 
fibrillation were more common in Group B. (Table 
1). After weaning from bypass, potassium was 
significantly higher in Group B (5.8± 0.8 vs. 3.7± 
0.4, P<0.001). PH was lower in Group B (7.3± 0.04 
vs. 7.37± 0.06; p <0.001). Sodium Bicarbonate 
levels were lower in Group B (19± 4 vs. 25± 5; p 
<0.001).  
Postoperative mechanical ventilation, ICU, and 
hospital stay were significantly longer in Group B 
(Table 2). Group B had a higher postoperative 
wound infection and mortality (Table 2).
Table 3: Postoperative echocardiographic data. Data were presented as mean and standard deviation 
Group A (n= 135) Group B (n= 166) P-value 
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Echocardiographic data 
There were no differences in the ejection 
fraction between groups in the postoperative 
period and during the 3- and 6-months follow-up. 
The left atrial diameter was significantly higher in 
Group B and left ventricular end-systolic diameter 
were lower in Group B. (Table 3) 
Discussion 
This study was performed on 301 patients to 
compare Custodiol® versus intermittent cold 
blood cardioplegia. Custodiol cardioplegia was 
associated with lower post-bypass arrhythmia, 
shorter mechanical ventilation, ICU, and hospital 
stay. Blood cardioplegia has been used to protect 
the myocardium. Although, every 15–20 min the 
surgical procedure is suspended for repeated 
doses. For the long and technically complex case, 
such as double valve replacement, an 
uninterrupted surgery is desirable, making 
Custodiol® an attractive option. However, there is 
no agreement between surgeons about the ideal 
cardioplegic solutions [8]. In this study, surgeons' 
preferences and beliefs affected the 
administration of cardioplegia in both groups. 
Some surgeons believe that blood cardioplegia 
offers better myocardial protection in old age and 
hypertrophied left ventricle, hence the difference 
in age and valve lesion distribution between 
groups.  
In our study, on coming off bypass, the 
arrhythmias were more common in the cold blood 
cardioplegia group. Del Nido and associates 
believe that postoperative conduction 
disturbances are associated with inadequate 
intraoperative myocardial protection, and hearts 
with good myocardial protection usually 
spontaneously defibrillate [9]. Sakata and 
coworkers evaluated the effect of HTK solution for 
complex cardiac surgery. They found more 
spontaneous defibrillation and lower requirement 
of inotropic drugs compared with cold blood 
cardioplegia [10]. 
In our study, about half of cases in Custodiol 
group returned to sinus rhythm (50%) after the 
use of DC, while (26.7%) of cases in the cold blood 
cardioplegia group. In a randomized study, 
markers of myocardial injury were measured and 
demonstrated that Custodiol in elective double 
valve surgery protects the myocardium equally 
well compared to repetitive antegrade cold blood 
cardioplegia. Braathen and associates found that 
spontaneous ventricular fibrillation after the 
cross-clamp removal in patients receiving HTK was 
significantly increased. After cross-clamp removal, 
this increase in fibrillation has been linked to 
oxidative stress and alteration of electrolyte 
concentration across the cell membranes. 
Conduction disturbances were associated with 
inadequate intraoperative myocardial protection 
caused by heterogeneous reperfusion and low 
ATP levels. Despite this, spontaneous ventricular 
fibrillation did not influence the release of 
myocardial enzymes compared to blood 
cardioplegia [11]. Our study reported VF as the 
first rhythm after reperfusion with cold blood 
cardioplegia, which was similar to Liu and 
coworkers. The reason for this is not clear. Some 
authors have suggested that VF after reperfusion 
may be an indication of inadequate myocardial 
protection [12]. 
There were statistically significant differences 
between both studied groups regarding 
ventilation time, hospital stay, and length of ICU 
stay. Li and associates found a shorter ICU stay 
with less mortality with Custodiol cardioplegia 
than cold blood cardioplegia because of low 
inotropic supports and postoperative 
complications in their cases with complex cardiac 
surgeries [13]. However, Kuslu and colleagues 
found both groups had the same results regarding 
the duration of mechanical ventilation and length 
of ICU stay; however, they studied pediatric 
patients with congenital heart diseases [14]. 
In this study, there was a significant statistical 
difference in arterial blood gases between both 
groups. Acidosis and hyperkalemia were common 
in the cold blood cardioplegia group. Other studies 
showed decreased serum sodium, but there was 
no significant change in osmolality, suggesting 
isotonic hyponatremia. Research suggested the 
use of hemofilter on the cardiopulmonary bypass 





In our study, postoperative complications such 
as wound turbid seroma were reported with the 
cold blood cardioplegia group. Sansone and 
colleagues reported lower mortality in patients 
undergoing complex cardiac surgery using 
Custodiol® compared with those patients using 
cold blood cardioplegia, which was similar to our 
study [15, 16]. 
In this study, postoperative echocardiographic 
data, including LV function and LV dimensions, 
were comparable between groups. Saitoh and 
coworkers proved that the preservation of 
Custodiol solution protects the myocardium and 
the coronary artery endothelium [17]. Von Oppell 
and coworkers stored cultures of human 
endothelium cells in different cardioplegic 
solutions and temperatures. According to their 
findings, the best available solution for 
hypothermic endothelium cell preservation is 
Custodiol, which was compatible with other 
studies [18]. 
Limitations of the study: 
The study is not a randomized trial, and 
surgeons' selection biased patients' distribution 
between groups. Several factors could have 
affected the outcomes other than the cardioplegic 
solutions. Moreover, the study is limited by being 
a single-center experience. However, the study 
showed the safety and feasibility of using 
Custodiol cardioplegia in double valve surgery. 
Conclusion 
A single dose cardioplegia strategy for 
myocardial protection (Custodiol®) could be 
beneficial for complex cardiac surgery 
performance.  A larger randomized trial is 
recommended to confirm our finding. 
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